The new guideline for evaluating effects of psychotropic drugs on the performance to drive a motor vehicle in Japan: Comparison with US FDA guideline
Open Access
- 14 April 2023
- journal article
- review article
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 43 (2) , 172-176
Abstract
In December 2022, the new guideline for evaluating the effect of psychotropic drugs on the performance to drive a motor vehicle was issued by the Ministry of Health, Labour and Welfare (MHLW) and implemented in Japan. Of the safety information, information on the influence of medications on driving performance is particularly important because it can be relevant to the social functioning of patients. In principle, the package inserts of medications are designed based on evidence and provide precautions regarding the operation of heavy machinery such as automobiles in Japan, the United States, and Europe. The effects of medications on driving performance are generally evaluated in a tiered approach involving nonclinical and clinical studies. Because of the wide variety of functional domains involved in automobile driving, the selection of evaluation methods for a given medication depends on their characteristics, which is a complicated method. Therefore, to evaluate the effects of psychotropic drugs on driving performance efficiently and appropriately, we developed the MHLW guideline that specifically defines the evaluation methods used in pharmacological studies, the neuropsychological tests used in pharmacodynamic studies, and the situations in which driving studies are necessary. Regarding the planning of appropriate drug development strategies, we review the background of the MHLW guideline and its differences from the US Food and Drug Administration (FDA) guideline.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP21mk0101137h0003, JP22mk0101227h0001)
This publication has 14 references indexed in Scilit:
- Validity and reliability of a driving simulator for evaluating the influence of medicinal drugs on driving performancePsychopharmacology, 2020
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia2020
- Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysisMolecular Psychiatry, 2020
- Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development2018
- Evaluation method regarding the effect of psychotropic drugs on driving performance: A literature reviewPsychiatry and Clinical Neurosciences, 2018
- Driving performance of stable outpatients with depression undergoing real‐world treatmentPsychiatry and Clinical Neurosciences, 2018
- A brief history of antidepressant drug development: from tricyclics to beyond ketamineActa Neuropsychiatrica, 2018
- Mobility behaviour and driving status of patients with mental disorders – an exploratory studyInternational Journal of Psychiatry in Clinical Practice, 2015
- Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysisThe Lancet Psychiatry, 2014
- Drugged Driving Expert Panel Report: A Consensus Protocol for Assessing the Potential of Drugs to Impair Driving2011